Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Synthetic Blood International, Inc. (SYBD) -- Ignore unavailable to you. Want to Upgrade?

To: Terry Vellequette who wrote (62)	5/24/1999 9:19:00 AM
From: taylorfife	Read Replies (2) \| Respond to of 91

New Shares. Any comments? KETTERING, Ohio--(BUSINESS WIRE)--May 24, 1999--Synthetic Blood International Inc. (OTCBB:SYBD - news) announced today that it will seek shareholder approval through a proxy mailing for the issuance of up to 10 million shares of preferred, convertible stock. This new stock will be used to help secure future financing for product development and clinical trials. ''Private and institutional investors have expressed interest in financing further development of our products up to the corporate partner stage,'' said Robert Nicora, SYBD president. ''The ability to issue preferred, convertible stock will aid in securing this financing without diluting existing common stock.'' Approval to issue preferred stock does not affect plans for a current, private placement which is expected to result in an announcement soon. Rather, it will be used to secure additional funding in the future. SYBD currently is developing three products: Oxycyte , a perfluorocarbon-based blood substitute; Fluorovent, a perfluorocarbon liquid ventilation product; and an implantable glucose biosensor for continuous monitoring of blood glucose levels in diabetics. Additionally, the company recently announced its intention to form a new venture to acquire therapeutic nitric oxide technology. Synthetic Blood International is located in Kettering, Ohio, with West Coast offices and laboratories in Newport Beach, Calif. The company's stock is traded on the OTC Electronic Bulletin Board, symbol SYBD. The company's Web site is http://www/sybd.com and e-mail address is sybd@siscom.net. Contact: